Real-World Study of the Safety and Efficacy of Surufatinib in the Treatment of Neuroendocrine Tumors

Inclusion Criteria: * Patients with pathologically or cytologically confirmed neuroendocrine tumors; * At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; * Life expectancy ≥ 12 weeks; * Adequate organ and bone marrow function Exclusion Criteria: * Participation in other drug clinical trials with investigational drug treatment within the past 4 weeks; * History of other malignancies within the past 5 years, except for curatively resected basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ; * Patients with contraindications to surufatinib (e.g., active bleeding, ulcer, intestinal perforation, intestinal obstruction, medically uncontrolled hypertension, grade III-IV cardiac dysfunction, within 30 days after major surgery, severe hepatic or renal impairment, etc.); * Presence of any disease or condition that affects drug absorption, or inability to take surufatinib orally; * Any condition deemed by the investigator as unsuitable for study drug treatment.